KR100826818B1 - 락탐 화합물 및 이를 함유하는 당뇨병 치료제 - Google Patents

락탐 화합물 및 이를 함유하는 당뇨병 치료제 Download PDF

Info

Publication number
KR100826818B1
KR100826818B1 KR1020037007327A KR20037007327A KR100826818B1 KR 100826818 B1 KR100826818 B1 KR 100826818B1 KR 1020037007327 A KR1020037007327 A KR 1020037007327A KR 20037007327 A KR20037007327 A KR 20037007327A KR 100826818 B1 KR100826818 B1 KR 100826818B1
Authority
KR
South Korea
Prior art keywords
group
substituent
formula
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020037007327A
Other languages
English (en)
Korean (ko)
Other versions
KR20030051893A (ko
Inventor
이이노유키오
이케노우에다카오
곤도노부오
마쓰에다히로유키
하타나카도시히로
히라마류스케
마스자와요코
오타후미오
야마자키아키요
Original Assignee
아지노모토 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아지노모토 가부시키가이샤 filed Critical 아지노모토 가부시키가이샤
Publication of KR20030051893A publication Critical patent/KR20030051893A/ko
Application granted granted Critical
Publication of KR100826818B1 publication Critical patent/KR100826818B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyrrole Compounds (AREA)
KR1020037007327A 2000-12-01 2001-11-29 락탐 화합물 및 이를 함유하는 당뇨병 치료제 Expired - Fee Related KR100826818B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JPJP-P-2000-00367175 2000-12-01
JP2000367175 2000-12-01
PCT/JP2001/010435 WO2002044180A1 (en) 2000-12-01 2001-11-29 Lactam compounds and medicinal use thereof

Publications (2)

Publication Number Publication Date
KR20030051893A KR20030051893A (ko) 2003-06-25
KR100826818B1 true KR100826818B1 (ko) 2008-05-02

Family

ID=18837660

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020037007327A Expired - Fee Related KR100826818B1 (ko) 2000-12-01 2001-11-29 락탐 화합물 및 이를 함유하는 당뇨병 치료제

Country Status (26)

Country Link
US (3) US7153850B2 (enExample)
EP (1) EP1346993B1 (enExample)
JP (2) JP3826400B2 (enExample)
KR (1) KR100826818B1 (enExample)
CN (2) CN1269818C (enExample)
AT (1) ATE446297T1 (enExample)
AU (3) AU1850202A (enExample)
BG (1) BG107857A (enExample)
BR (1) BR0115852A (enExample)
CA (1) CA2430124C (enExample)
CZ (1) CZ20031520A3 (enExample)
DE (1) DE60140270D1 (enExample)
ES (1) ES2331299T3 (enExample)
HU (1) HUP0400806A3 (enExample)
IL (1) IL156158A0 (enExample)
MX (1) MXPA03004876A (enExample)
NO (1) NO325401B1 (enExample)
NZ (1) NZ526164A (enExample)
PL (1) PL362835A1 (enExample)
RU (1) RU2287530C2 (enExample)
SK (1) SK6582003A3 (enExample)
TW (1) TWI241302B (enExample)
UA (1) UA76969C2 (enExample)
WO (1) WO2002044180A1 (enExample)
YU (1) YU42603A (enExample)
ZA (1) ZA200304100B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2331299T3 (es) * 2000-12-01 2009-12-29 Ajinomoto Co., Inc. Compuestos de lactama y su uso medico.
MXPA05008363A (es) * 2003-02-07 2005-12-06 Ajinomoto Kk Agentes terapeuticos para diabetes.
CA2544310A1 (en) 2003-10-31 2005-05-12 Ajinomoto Co., Inc. New fused polycyclic compounds having a heterocyclic ring(s) and pharmaceutical use thereof
JPWO2005068467A1 (ja) * 2004-01-14 2007-12-27 味の素株式会社 新規縮環化合物
JP2008515939A (ja) * 2004-10-13 2008-05-15 エフ．ホフマン−ラ ロシュ アーゲー Ｃｄｋ２及び血管形成の阻害剤として、及び乳癌、結腸癌及び前立腺癌の治療に有用な２置換ピラゾロベンゾジアゼピン
NZ563131A (en) * 2005-04-28 2010-09-30 Ajinomoto Kk Tricyclic lactam compound as a hypoglycemic agent
EP2157092A4 (en) 2007-04-11 2011-04-13 Ajinomoto Kk Remedy for diabetes
WO2008139574A1 (ja) * 2007-04-27 2008-11-20 Ajinomoto Co., Inc. ラクタム化合物の結晶形およびその製造方法
WO2008139575A1 (ja) * 2007-04-27 2008-11-20 Ajinomoto Co., Inc. 経口投与用製剤
WO2008136394A1 (ja) * 2007-04-27 2008-11-13 Ajinomoto Co., Inc. ラクタム化合物の製造方法及びその製造中間体
CN101619041B (zh) * 2008-07-02 2012-07-04 重庆华邦制药股份有限公司 一种二酮基含氮环化合物的合成方法及其中间体
JP2012180282A (ja) * 2009-07-02 2012-09-20 Ajinomoto Co Inc ラクタム化合物の製造方法およびその製造中間体
JP2012180283A (ja) * 2009-07-02 2012-09-20 Ajinomoto Co Inc ラクタム化合物の製造方法およびその製造中間体
RU2017126027A (ru) * 2014-12-22 2019-01-24 ЕА Фарма Ко., Лтд. Лекарственное средство для лечения расстройств эпителия роговицы
AU2017208970A1 (en) 2016-01-18 2018-08-02 Arisan Therapeutics Adamatane derivatives for the treatment of filovirus infection
US11548893B2 (en) 2017-07-15 2023-01-10 Arisan Therapeutics Inc. Enantiomerically pure adamantane carboxamides for the treatment of filovirus infection
WO2020151671A1 (en) * 2019-01-23 2020-07-30 Glycolysis Biomed Co., Ltd Beta-lactam compounds or salts thereof for use in long-acting prevention or treatment of a glucose metabolism disorder

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11171776A (ja) 1997-12-05 1999-06-29 Iyaku Bunshi Sekkei Kenkyusho:Kk 糖尿病の予防・治療剤

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US189597A (en) * 1877-04-17 Improvement in portable wash-stands
US48847A (en) * 1865-07-18 Improvement in vessels for reception and transportation of night-soil
GB8720414D0 (en) * 1987-08-28 1987-10-07 Roussel Lab Ltd Chemical compounds
US5719296A (en) * 1995-10-30 1998-02-17 Merck & Co., Inc. Pseudopeptide lactam inhibitors of peptide binding to MHC class II proteins
NZ502448A (en) 1997-07-30 2002-12-20 Wyeth Corp Tricyclic vasopressin agonists and medicaments containing these compounds
ES2331299T3 (es) * 2000-12-01 2009-12-29 Ajinomoto Co., Inc. Compuestos de lactama y su uso medico.
MXPA05008363A (es) 2003-02-07 2005-12-06 Ajinomoto Kk Agentes terapeuticos para diabetes.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11171776A (ja) 1997-12-05 1999-06-29 Iyaku Bunshi Sekkei Kenkyusho:Kk 糖尿病の予防・治療剤

Also Published As

Publication number Publication date
RU2287530C2 (ru) 2006-11-20
PL362835A1 (en) 2004-11-02
AU2006241377A1 (en) 2006-12-14
US7326701B2 (en) 2008-02-05
US7153850B2 (en) 2006-12-26
YU42603A (sh) 2006-03-03
CA2430124C (en) 2011-01-11
JP2006213732A (ja) 2006-08-17
ZA200304100B (en) 2004-08-22
NO20032439D0 (no) 2003-05-28
US7632830B2 (en) 2009-12-15
US20040048847A1 (en) 2004-03-11
JP3826400B2 (ja) 2006-09-27
ATE446297T1 (de) 2009-11-15
CN1269818C (zh) 2006-08-16
CN100577651C (zh) 2010-01-06
AU2006241377B2 (en) 2009-01-08
US20060189597A1 (en) 2006-08-24
AU2002218502B2 (en) 2006-09-21
BR0115852A (pt) 2003-12-23
IL156158A0 (en) 2003-12-23
EP1346993A1 (en) 2003-09-24
CA2430124A1 (en) 2002-06-06
US20080096862A1 (en) 2008-04-24
JPWO2002044180A1 (ja) 2004-04-02
NO20032439L (no) 2003-07-18
SK6582003A3 (en) 2003-09-11
JP4505753B2 (ja) 2010-07-21
MXPA03004876A (es) 2004-01-27
UA76969C2 (en) 2006-10-16
ES2331299T3 (es) 2009-12-29
DE60140270D1 (de) 2009-12-03
CZ20031520A3 (cs) 2003-10-15
EP1346993B1 (en) 2009-10-21
CN1487940A (zh) 2004-04-07
KR20030051893A (ko) 2003-06-25
EP1346993A4 (en) 2005-12-21
AU1850202A (en) 2002-06-11
NZ526164A (en) 2004-09-24
HUP0400806A3 (en) 2007-11-28
HUP0400806A2 (hu) 2004-07-28
CN1911915A (zh) 2007-02-14
NO325401B1 (no) 2008-04-21
WO2002044180A1 (en) 2002-06-06
TWI241302B (en) 2005-10-11
BG107857A (bg) 2004-06-30

Similar Documents

Publication Publication Date Title
KR100826818B1 (ko) 락탐 화합물 및 이를 함유하는 당뇨병 치료제
KR101991326B1 (ko) 오피오이드 수용체 리간드와 그 용도 및 제조방법
WO2020177653A1 (zh) 吡嗪类衍生物及其在抑制shp2中的应用
KR100627608B1 (ko) Ｎ,ｎ-치환 환상아민유도체
KR20110037883A (ko) 잔틴 옥시다아제 저해제로서 효과적인 신규 화합물, 그 제조방법 및 그를 함유하는 약제학적 조성물
CN111018891B (zh) 作为长效dpp-iv抑制剂的取代的氨基六元饱和杂脂环类
CN116323608A (zh) Ampk活化剂
JP2010070514A (ja) ピラゾール誘導体及びその医薬用途
CN114948953A (zh) 一种杂原子取代芳香类化合物及其盐的用途
US20060258637A1 (en) Fused polycyclic compounds
JP4345097B2 (ja) 縮合多環式化合物およびその医薬用途
CN111662239B (zh) 1,2,4-三唑类化合物及其制法和药物用途
CN107304180B (zh) 苯甲酰胺类衍生物、其制备方法及其在医药上的用途
CN117999072A (zh) β肾上腺素能激动剂和其使用方法
HK40061204B (zh) 吡嗪类衍生物及其在抑制shp2中的应用
HK1236935B (zh) 作为长效dpp-iv抑制剂的取代的氨基六元饱和杂脂环类
CN107417669A (zh) 3-(1h-吲唑)-四氢嘧啶-2-酮类化合物、其制备方法及其用途

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20110426

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20110426

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000